Zydus Cadila has received final approval from the USFDA to market Pyridostigmine Bromide Tablets USP, 60 mg. The tablets are used in treatment of neurological disorders. The market for Pyridostigmine Bromide is estimated at USD 27.9 million.
Company Profile : Cadila Healthcare Ltd
Leave a Reply